JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Director Eric Crombez of Abeona Therapeutics INC (NASDAQ:ABEO) sold 4,718 shares of common stock on August 14, 2025. The shares were sold at prices ranging from $6.77 to $7.05, realizing approximately $32,683. The transaction occurred as the stock trades near its 52-week high of $7.32, with the company’s market capitalization now standing at $367 million. According to InvestingPro, the stock has shown remarkable strength with a 15.5% gain in the past week alone.
The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following the sale, Crombez directly owns 42,427 shares of Abeona Therapeutics.
The sale was executed to cover tax obligations associated with the vesting of restricted stock awards.
In other recent news, Abeona Therapeutics reported an unexpected profit for Q2 2025. The company achieved an earnings per share (EPS) of $1.71, which was a significant surprise compared to the forecasted EPS of -$0.38. This marks a 550% surprise in earnings, a notable development for investors. Revenue for the quarter reached $400,000, despite no revenue being forecasted. These earnings results have captured attention due to the unexpected profitability and revenue figures. Abeona’s recent performance highlights the company’s ability to surpass expectations, which may influence future analyst projections. The earnings announcement was a key moment for the company, reflecting a positive financial outcome. Investors and analysts will likely watch Abeona’s future developments closely following this earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.